Medicare Drug Coverage Appeals May Follow Medicaid Model – McClellan
Executive Summary
State Medicaid prior authorization procedures controlling the coverage of COX-2 inhibitors are a possible model for appeals processes under the Medicare drug benefit, Centers for Medicare & Medicaid Services Administrator Mark McClellan told the Senate Finance Committee
You may also be interested in...
USP Responding To Congress’ Questions On Medicare Formulary Guidelines
The U.S. Pharmacopeia has been providing congressional committees with information as it moves toward finalizing its model formulary guidelines for the Medicare prescription drug benefit
USP Responding To Congress’ Questions On Medicare Formulary Guidelines
The U.S. Pharmacopeia has been providing congressional committees with information as it moves toward finalizing its model formulary guidelines for the Medicare prescription drug benefit
USP Working Toward Medicare Formulary PBMs Can Use, McClellan Says
U.S. Pharmacopeia will make sure its model Medicare formulary guidelines "work" for prescription drug plan sponsors as it constructs the final version, Centers for Medicare & Medicaid Services Administrator Mark McClellan says